The Implications of a Growing Evidence Base for Drug Use in Elderly Patients. Part 4. Vitamin D and Bisphosphonates for Fractures and Osteoporosis

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2006 May 4

PMID 16669844

Citations 1

Authors

J K Dhesi

T J Allain

A A Mangoni

S H D Jackson

Affiliations

Soon will be listed here.

Abstract

Fractures are common in elderly subjects, disabling and occasionally fatal. Their incidence increases exponentially with age, with the commonest affected sites being the wrist, vertebrae, hip and humerus. Of these, hip fractures are the most relevant in terms of morbidity and financial cost. The increase in fracture rate with age is believed to result predominantly from age-related increases in the incidence of osteoporosis and falls. This article reviews the evidence for the use of vitamin D and bisphosphonates for the prevention of bone fractures and osteoporosis in elderly patients.

Citing Articles

Prescribing for older people.

Milton J, Hill-Smith I, Jackson S BMJ. 2008; 336(7644):606-9.

PMID: 18340075 PMC: 2267940. DOI: 10.1136/bmj.39503.424653.80.

References

Ringe J, Dorst A, Faber H, Ibach K . Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2003; 24(2):110-3. DOI: 10.1007/s00296-003-0388-y. View

Dawson-Hughes B, Harris S, Krall E, Dallal G . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997; 337(10):670-6. DOI: 10.1056/NEJM199709043371003. View

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View

Trivedi D, Doll R, Khaw K . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003; 326(7387):469. PMC: 150177. DOI: 10.1136/bmj.326.7387.469. View

Scharla S . Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int. 1999; 8 Suppl 2:S7-12. DOI: 10.1007/pl00022726. View

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Whyte M, Haddad Jr J . Variable potency of intramuscular vitamin D preparations. N Engl J Med. 1979; 300(3):142. DOI: 10.1056/NEJM197901183000316. View

Tilyard M, SPEARS G, Thomson J, Dovey S . Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992; 326(6):357-62. DOI: 10.1056/NEJM199202063260601. View

10.

Trang H, Cole D, Rubin L, Pierratos A, Siu S, Vieth R . Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998; 68(4):854-8. DOI: 10.1093/ajcn/68.4.854. View

11.

Baker M, McDONNELL H, Peacock M, Nordin B . Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br Med J. 1979; 1(6163):589. PMC: 1598358. DOI: 10.1136/bmj.1.6163.589. View

12.

Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-41. DOI: 10.1016/s0140-6736(96)07088-2. View

13.

Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007; 46(12):1852-7. DOI: 10.1093/rheumatology/kem240. View

14.

Ringe J . Vitamin D deficiency and osteopathies. Osteoporos Int. 1999; 8 Suppl 2:S35-9. DOI: 10.1007/pl00022731. View

15.

Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1999; 280(24):2077-82. DOI: 10.1001/jama.280.24.2077. View

16.

Vieth R . Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999; 69(5):842-56. DOI: 10.1093/ajcn/69.5.842. View

17.

Buist D, LaCroix A, Black D, Harris F, Blank J, Ensrud K . Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. J Am Geriatr Soc. 2000; 48(9):1126-31. DOI: 10.1111/j.1532-5415.2000.tb04790.x. View

18.

Heikinheimo R, Inkovaara J, Harju E, Haavisto M, Kaarela R, Kataja J . Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int. 1992; 51(2):105-10. DOI: 10.1007/BF00298497. View

19.

Lips P, Graafmans W, Ooms M, Bezemer P, Bouter L . Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1996; 124(4):400-6. DOI: 10.7326/0003-4819-124-4-199602150-00003. View

20.

Boonen S, McClung M, Eastell R, Fuleihan G, Barton I, Delmas P . Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004; 52(11):1832-9. DOI: 10.1111/j.1532-5415.2004.52506.x. View